Videos

This presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes: are a valid model of cardiomyocytes from the human heart, compatible with assays routinely used for testing cardiotoxicity and how together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds. view now

Current estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins us to discuss the ever-increasing numbers of poorly soluble drugs coming to market and utilising in silico and computational modelling to better predict absorption of new chemical entities. view now

Tenna Juul Schroder, Head of Department, Molecular Pharmacology, Lundbeck, shares her insights on compound management in an ever-changing organisation and discusses new compound management strategies involving outsourcing to CROs, to be able to support projects with a more flexible solution for hit finding. view now

In this interview Jose A Quiroz, Compound Manager at Dart Neuroscience, speaks to Pharma IQ about medicinal chemistry vial workflows, the latest advances at Dart Neuroscience in the field of compound tracking and distribution and the main challenges of automating compound sourcing. view now

Dr. Ronald Frank, Head of Research Group, Chemical Systems Biology, Leibniz- Institut fur Molekulare Pharmakologie (FMP), speaks to Pharma IQ about the EU-OPENSCREEN project initiative, funding and plans. view now

Oliver Peter, PhD, Group Head of Drug Discovery Biology at HTS Group, Actelion Pharmaceuticals, discusses biosample stabilisation, optimum data structures to store biosample information, challenges associated with low temperature storage and how to profit from compound management know-how. view now

Duncan McHale, Vice-President for Personalised Healthcare and Biomarkers, AstraZeneca, discusses the importance of biomarker discovery & validation, how close we are to ‘Personalised Medicine’, why sample quality is key, the rules of good biobanking, how we can improve biomarker research, what we should change and why, what’s stopping us bringing change and his top 3 priorities for the next 12 months. view now

With a focus on biobanking Maass outlines some common difficulties in isolating biomarkers from samples that have previously been stored in a bio/tissue bank; he shares his opinions on storage techniques for samples to get the best results. He also sheds light on the state of Roche’s internal biobank, discusses the extent to which Roche sources samples externally from biobanks, and the main difficulties/challenges with this. Finally, he gives some research-side advice for new or expanding biobanks. view now

In this section on companion diagnostics, Maass explains how CDx can help us to administer the right drug at the right time in the right dose to the right patient. He acknowledges the fact CDx is known to be costly and difficult to implement and utilise effectively and outlines the main problems and challenges. Maass also sets out the vital stages in translating biomarkers from the laboratory to the clinic – and the best ways of successfully validating them. view now

Gerd Maass, Vice President for R&D at Roche Pharmaceuticals, shares his views on advances in companion diagnostics, DNA sequencing and biobanking. Chapter 1 - DNA Sequencing view now

Bill Skinner and Toby Winchester, Senior Principal Scientists at Pfizer, join Pharma IQ, to discuss the clean up of the Pfizer compound file. view now